Page last updated: 2024-10-30

losartan and Neurilemmoma

losartan has been researched along with Neurilemmoma in 1 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Neurilemmoma: A neoplasm that arises from SCHWANN CELLS of the cranial, peripheral, and autonomic nerves. Clinically, these tumors may present as a cranial neuropathy, abdominal or soft tissue mass, intracranial lesion, or with spinal cord compression. Histologically, these tumors are encapsulated, highly vascular, and composed of a homogenous pattern of biphasic fusiform-shaped cells that may have a palisaded appearance. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp964-5)

Research Excerpts

ExcerptRelevanceReference
"Hearing loss is one of the most common symptoms of neurofibromatosis type 2 (NF2) caused by vestibular schwannomas (VSs)."5.62Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. ( Brown, A; Chen, J; Datta, M; Early, S; Gao, X; Ho, WW; Jain, RK; Landegger, LD; Lee, GY; Muzikansky, A; Plotkin, SR; Ren, J; Sagers, JE; Stankovic, KM; Stemmer-Rachamimov, A; Sun, Y; Vasilijic, S; Wu, L; Xu, L; Yin, Z; Zhang, L; Zhang, N; Zhang, Y; Zhou, W, 2021)
"Hearing loss is one of the most common symptoms of neurofibromatosis type 2 (NF2) caused by vestibular schwannomas (VSs)."1.62Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. ( Brown, A; Chen, J; Datta, M; Early, S; Gao, X; Ho, WW; Jain, RK; Landegger, LD; Lee, GY; Muzikansky, A; Plotkin, SR; Ren, J; Sagers, JE; Stankovic, KM; Stemmer-Rachamimov, A; Sun, Y; Vasilijic, S; Wu, L; Xu, L; Yin, Z; Zhang, L; Zhang, N; Zhang, Y; Zhou, W, 2021)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Wu, L1
Vasilijic, S1
Sun, Y1
Chen, J1
Landegger, LD1
Zhang, Y1
Zhou, W1
Ren, J1
Early, S1
Yin, Z1
Ho, WW1
Zhang, N1
Gao, X1
Lee, GY1
Datta, M1
Sagers, JE1
Brown, A1
Muzikansky, A1
Stemmer-Rachamimov, A1
Zhang, L1
Plotkin, SR1
Jain, RK1
Stankovic, KM1
Xu, L1

Other Studies

1 other study available for losartan and Neurilemmoma

ArticleYear
Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models.
    Science translational medicine, 2021, 07-14, Volume: 13, Issue:602

    Topics: Animals; Hearing Loss; Humans; Losartan; Mice; Neurilemmoma; Neurofibromatosis 2; Prospective Studie

2021